Enfermedades Bulosas Autoinmunes en el contexto de COVID-19

Journal Scan / Consensus and Guidelines · June 28, 2020

Management of Autoimmune Bullous Diseases During the COVID-19 Pandemic

Journal of the European Academy of Dermatology and Venereology: JEADV

TAKE-HOME MESSAGE

• The management of autoimmune bullous disease on immunosuppressive therapy during the COVID-19 pandemic is a challenge for physicians. Although immunosuppressive therapy can inhibit antiviral immunity, it has also been postulated that immunosuppressive drugs may decrease the likelihood of lung injury caused by the SARS-CoV-2 virus.

• For patients without active infection, this expert panel recommends continuing immunomodulatory therapy while adhering to the advice of local health authorities and practicing social distancing. In the case of infection, azathioprine, mycophenolate, cyclophosphamide, methotrexate, and cyclosporine can be stopped, whereas systemic corticosteroids, dapsone, tetracyclines, colchicine, and IVIG can be continued.

– Margaret Hammond, MD

Abstract

Autoimmune bullous diseases (AIBDs) are potentially life‐threatening disorders comprising intra‐epidermal/epithelial (pemphigus) and sub‐epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non‐steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches.

Journal of the European Academy of Dermatology and Venereology: JEADV

Expert Recommendations for the Management of Autoimmune Bullous Diseases During the COVID-19 Pandemic

J Eur Acad Dermatol Venereol 2020 Apr 25;[EPub Ahead of Print], M Kasperkiewicz, E Schmidt, JA Fairley, P Joly, AS Payne, ML Yale, D Zillikens, DT Woodley 

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.